Navigation Links
Amylin Pharmaceuticals Reports First Quarter Financial Results
Date:4/21/2008

SAN DIEGO, April 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended March 31, 2008. The Company reported total revenue of $197.2 million for the first quarter, which includes net product sales of $178.7 million. Net loss for the quarter ended March 31, 2008 was $68.8 million, or $0.51 per share. At March 31, 2008, the Company held cash, cash equivalents and short-term investments of approximately $1,033.9 million.

"We have made steady progress in the first quarter of 2008 across near-, mid- and long-term opportunities, executing against the strategy detailed earlier this year to build Amylin's diabetes portfolio and establish our presence in the obesity field," said Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals. "BYETTA sales were lower than expected this quarter in part due to wholesaler buying patterns. We remain confident that we are taking the right steps to build sustainable BYETTA growth over time."

Bradbury continued, "Importantly, we achieved a significant milestone towards our efforts to submit the NDA for exenatide once weekly. We have manufactured exenatide once weekly product at commercial scale in our facility in Ohio and will begin supplying material from the facility to support ongoing and planned clinical programs by the third quarter."

Financial results

Net product sales of $178.7 million for the quarter ended March 31, 2008 include $158.5 million for BYETTA(R) (exenatide) injection and $20.2 million for SYMLIN(R) (pramlintide acetate) injection. This compares to net product sales of $162.0 million, consisting of $146.5 million for BYETTA and $15.5 million for SYMLIN for the same p
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
2. Amylin Pharmaceuticals to Webcast Third Quarter Results
3. Amylin Pharmaceuticals to Webcast Conference Call
4. Amylin Pharmaceuticals to Present at Research & Development Day
5. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
6. Amylin Pharmaceuticals Reports 2007 Financial Results
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... It,s estimated that as many as 10 million older ... of loneliness and isolation. , However, new research ... retired older Americans for six years found that ... of depression by more than 30 percent. , "That,s ... State University professor of telecommunication, information studies and media ...
(Date:4/17/2014)... from Boston University School of Medicine (BUSM) have ... consumption in an experimental model. The findings, reported ... Alcohol Abuse , may lead to more effective ... is one of the leading causes of illness ... negative economic impact by limiting the productivity of ...
(Date:4/17/2014)... by Cesar A. Arias, M.D., Ph.D., at The University ... identified a new superbug that caused a bloodstream infection ... April 17 issue of The New England Journal ... of a class of highly-resistant bacteria known as methicillin-resistant ... major cause of hospital and community-associated infections. The superbug ...
(Date:4/17/2014)... therapy improves general blood flow and alleviates muscle ... researchers at the University of Illinois at Chicago. ... print in the Archives of Physical Medicine ... vascular function in people who had not exercised, ... of their level of physical activity. , Improved ...
(Date:4/17/2014)... 17, 2014 Giving patients adrenaline after they suffer a ... their prospects of surviving long-term, according to new research ... of patients who have a cardiac arrest get adrenaline, ... arrest for decades," said Dr. Steve Lin, an emergency ... despite advances in medical treatment, long-term survival rates of ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:New MRSA superbug emerges in Brazil 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2
... with Rare Hair Loss Disease, SCARBOROUGH, N.Y., Feb. ... wants you to notice. "February is the perfect time ... auto-immune skin disease,alopecia areata," encourages Chassin, founder and president ... are healthier when,women and the people who love them ...
... healthy people, both sleepiness and vigilance show a relationship ... core body temperature is high during the daytime, skin ... Conversely, when core body temperature is low at night ... sleep. Among those suffering from narcolepsy, however, direct ...
... NJ Business Leaders Learn How Their Employee Health ... 31 Business owners and human,resource executives grappling ... competitive and cost effective found out how their ... at Embassy Suites,Parsippany. Scott Rappoport, a 25-year veteran ...
... is enthused about Part D,s success, but critics say ... -- The three-year-old Medicare Part D drug program is ... costs for the program fall, U.S. health officials announced ... considerably lower than originally projections, enrollment continues to rise ...
... Jan. 31 Today Genghis Grill will launch ... 20 locations nationwide -- Asian,Chili Scallop Bowl. The ... with a,variety of fresh heart-healthy ingredients from Khan,s ... Three more recipes are scheduled to,launch nationwide starting ...
... director of the National Alliance on Mental Illness ... circus and reckless speculation has surrounded events in ... family. Professional ethics,require that mental health professionals who ... diagnose them. A person,s treatment and recovery,from any ...
Cached Medicine News:Health News:Bald Valentine Offers Loving Tips in Maryland 2Health News:Changes in narcoleptics' skin, core body temperatures affect their vigilance and sleepiness 2Health News:Changes in narcoleptics' skin, core body temperatures affect their vigilance and sleepiness 3Health News:Key to Attracting and Retaining Quality Employees: Benefits 2Health News:Key to Attracting and Retaining Quality Employees: Benefits 3Health News:Medicare's Drug Program Enrollment Up, Costs Down 2Health News:Medicare's Drug Program Enrollment Up, Costs Down 3Health News:Genghis Grill Offers Recipes Featuring Heart Healthy Dining Options 2Health News:Britney Spears: Let's Talk About All of Us 2
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, wireless ... F. Doman , Executive Chairman and Interim CEO of ... Markets, Tenth Annual Equity Conference. Mr. ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... from MedImmune, PRINCETON, N.J., Aug. 12 ... its partner MedImmune, Inc. has,initiated a Phase 2A ... of systemic lupus erythematosus (SLE or lupus).,MEDI-545 is ... Human,Antibody Development System(R). Under the terms of the ...
... Therapeutics, Inc., a,privately held immunotherapeutics discovery and ... of novel immunotherapies for the,treatment of cancer, ... agreements with the Memorial Sloan-Kettering Cancer Center,s,Sloan-Kettering ... http://www.newscom.com/cgi-bin/prnh/20080812/LATU515LOGO ), The first license ...
Cached Medicine Technology:Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 2Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 3Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus 4MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research 2
The Bard Ellik Bladder Evacuator is designed for ease of maneuverability during the removal of tissue sections during transurethral prostatectomy, TURPs, bladder biopsy, etc....
Inquire...
... BT table comes in two modelsthe BT4, ... the BT5, which offers five. With the ... adjust to suit your needs. Both ... controls, side rails, ankle/foot supports, adjustable arm ...
UROSKOP Access, the dedicated urodiagnostic table with truly unrestricted patient access optimizes nearly all diagnostic and interventional procedures....
Medicine Products: